| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 05/28/2009 | WO2009065181A1 Nanostructures suitable for delivery of agents |
| 05/28/2009 | WO2009048959A8 Rapid acting injectable insulin compositions |
| 05/28/2009 | WO2009048280A3 Long acting hyaluronic acid - peptide conjugate |
| 05/28/2009 | WO2009046880A3 Use of a peptide as a therapeutic agent |
| 05/28/2009 | WO2009046877A3 Use of a histrelin and leuprolide as therapeutic agents |
| 05/28/2009 | WO2009046822A3 Use of the peptide ymdgtmsqv as a therapeutic agent |
| 05/28/2009 | WO2009043527A3 Therapeutic use of human growth hormone 1-43 |
| 05/28/2009 | WO2009043521A3 Use of urocortin iii and urocortin i as therapeutic agents |
| 05/28/2009 | WO2009043506A3 Use of a peptide as a therapeutic agent |
| 05/28/2009 | WO2009043456A3 Use of a peptide as a therapeutic agent |
| 05/28/2009 | WO2009042294A3 Tissue-nonspecific alkaline phosphatase (tnap) activators and uses thereof |
| 05/28/2009 | WO2009040051A3 Use of the peptide rfmwmk alone or in combination with the peptide ymdgtmsqv as a therapeutic agent |
| 05/28/2009 | WO2009040023A3 Use of galnon as a therapeutic agent |
| 05/28/2009 | WO2009040005A3 Use of the peptide rfmwmr as a therapeutic agent |
| 05/28/2009 | WO2009039985A3 Therapeutic uses of urocortin ii |
| 05/28/2009 | WO2009039984A3 Therapeutic uses of urocortin ii and kisspeptin ( 27-54 ) |
| 05/28/2009 | WO2009039983A3 Use of a peptide as a therapeutic agent |
| 05/28/2009 | WO2009039978A3 Therapeutic use of neuropeptide ei and acth 7-38 and compositions thereof |
| 05/28/2009 | WO2009033747A3 Use of a peptide as a therapeutic agent |
| 05/28/2009 | WO2009033660A3 Use of octreotide as a therapeutic agent |
| 05/28/2009 | WO2009010968A3 Disease treatment via antimicrobial peptides or their inhibitors |
| 05/28/2009 | WO2009005793A3 Tissue specific peptide conjugates and methods |
| 05/28/2009 | WO2008156638A3 Method of treating disorders that would benefit from increased levels of bilirubin in a subject |
| 05/28/2009 | WO2008112162A3 Compositions and methods for treating diseases, disorders or conditions characterized by myelin degeneration, myelin deficiency or loss |
| 05/28/2009 | WO2008097541A4 Variants derived from actriib and uses therefor |
| 05/28/2009 | WO2008073620A3 Manufacturing process for the production of polypeptides expressed in insect cell-lines |
| 05/28/2009 | WO2007047834A3 Oral peptide conjugates for metabolic diseases |
| 05/28/2009 | WO2007008732A3 Compositions and methods for suppressing axonal growth inhibition |
| 05/28/2009 | WO2006037052A3 Modulating mxa expression |
| 05/28/2009 | WO2005077099A3 Reduction of hiv-1 replication by a mutant apolipoprotein b mrna editing enzyme-catalytic polypeptide-like 3 g (apobec3g) |
| 05/28/2009 | US20090138978 Use of bridge-1 and activators and inhibitors thereof in the treatment of insulin deficiency and diabetes |
| 05/28/2009 | US20090138977 Pancreatic cancer targets and uses thereof |
| 05/28/2009 | US20090137835 Processes for intermediates for macrocyclic compounds |
| 05/28/2009 | US20090137817 Spatially-defined macrocyclic compounds useful for drug discovery |
| 05/28/2009 | US20090137788 Nucleotide sequences coding bacterial cell surface proteins for use in generating monoclonal antibodies for prevention and treatment of infection |
| 05/28/2009 | US20090137781 Method and Device for Producing a Thread from Silk Proteins |
| 05/28/2009 | US20090137779 Peptide inhibitors of thrombin as potent anticoagulants |
| 05/28/2009 | US20090137778 A HIV peptide consisting of 23 to 50 amino acid residues; trans-activator |
| 05/28/2009 | US20090137763 Glucosamine nucleotide sugars |
| 05/28/2009 | US20090137677 Abuse-resistant amphetamine prodrugs |
| 05/28/2009 | US20090137676 Abuse-resistant amphetamine prodrugs |
| 05/28/2009 | US20090137675 Abuse-resistant amphetamine prodrugs |
| 05/28/2009 | US20090137674 Administering L-lysine-d-amphetamine or salts |
| 05/28/2009 | US20090137673 Abuse-resistant amphetamine prodrugs |
| 05/28/2009 | US20090137672 Abuse-resistant amphetamine prodrugs |
| 05/28/2009 | US20090137619 Method for preventing and/or treating peripheral neuropathies induced by the administration of an anticancer agent |
| 05/28/2009 | US20090137536 Method for treating and preventing hyperparathyroidism |
| 05/28/2009 | US20090137518 Therapeutic Antiangiogenic Endostatin Compositions |
| 05/28/2009 | US20090137515 Abuse-resistant amphetamine prodrugs |
| 05/28/2009 | US20090137513 RNA Interference Mediated Inhibition of Acetyl-CoA-Carboxylase Gene Expression Using Short Interfering Nucleic Acid (siNA) |
| 05/28/2009 | US20090137512 nucleotide sequence complementary to a target RNA sequence and a second sequence chemically modified so it can no longer act as a guide sequence for mediating RNA interference, having complementarity to said first sequence; cancer, proliferative diseases |
| 05/28/2009 | US20090137511 RNA INTERFERENCE MEDIATED INHIBITION OF PLACENTAL GROWTH FACTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| 05/28/2009 | US20090137509 RNA INTERFERENCE MEDIATED INHIBITION OF PROLIFERATION CELL NUCLEAR ANTIGEN (PCNA) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| 05/28/2009 | US20090137508 Treatment of any disease that responds to modulation of gene expression, for example cancer, proliferative, inflammatory, metabolic, autoimmune, neurologic, ocular diseases; in vivo stability and bioavailability |
| 05/28/2009 | US20090137501 Resistance Genes |
| 05/28/2009 | US20090137495 Organic Compounds and Their Uses |
| 05/28/2009 | US20090137494 Tumor-activated prodrug compounds and treatment |
| 05/28/2009 | US20090137493 Inhibition of tumor metastases using protein kinase C (PKC) inhibitors |
| 05/28/2009 | US20090137492 Method to reduce the risk and/or severity of anthrax infection |
| 05/28/2009 | US20090137491 Abuse-resistant amphetamine prodrugs |
| 05/28/2009 | US20090137490 Abuse-resistant amphetamine prodrugs |
| 05/28/2009 | US20090137489 Abuse-resistant amphetamine prodrugs |
| 05/28/2009 | US20090137488 Abuse-resistant amphetamine prodrugs |
| 05/28/2009 | US20090137487 Abuse-resistant amphetamine prodrugs |
| 05/28/2009 | US20090137486 Abuse-resistant amphetamine prodrugs |
| 05/28/2009 | US20090137485 Antigens Targeted by Pathogenic T Cells in Type 1 Diabetes and Uses Thereof |
| 05/28/2009 | US20090137484 Neuronal Network-Interacting Peptide |
| 05/28/2009 | US20090137483 Antagonists of the bradykinin B1 receptor |
| 05/28/2009 | US20090137482 Biologically active peptide and agent containing the same |
| 05/28/2009 | US20090137481 Antimicrobial polypeptides |
| 05/28/2009 | US20090137480 Transdermal delivery system for dried particulate or lyophilized medications |
| 05/28/2009 | US20090137479 Methods of treating and diagnosing laminopathy |
| 05/28/2009 | US20090137478 Hormone normalization therapy and uses therefor |
| 05/28/2009 | US20090137477 Treatment of oropharyngeal candidiasis in cancer patients |
| 05/28/2009 | US20090137476 Apo-2 ligand variants and uses thereof |
| 05/28/2009 | US20090137475 Medicaments and proteins based on tgf-beta monomers for the treatment of wounds |
| 05/28/2009 | US20090137474 Use of polypeptides having antimicrobial activity |
| 05/28/2009 | US20090137473 Inhibition of microtubule protrusion in cancer cells |
| 05/28/2009 | US20090137472 Chimeric mhc protein and oligomer thereof |
| 05/28/2009 | US20090137471 Ngf variants |
| 05/28/2009 | US20090137470 Methods of treating cancer using notch pathway inhibitors |
| 05/28/2009 | US20090137469 Use of ADNF polypeptides for treating peripheral neurotoxicity |
| 05/28/2009 | US20090137468 Cytotoxic factors for modulating cell death |
| 05/28/2009 | US20090137467 Bipartite Inhibitors of Bacterial RNA Polymerase |
| 05/28/2009 | US20090137466 Use of GLP-1, Exendin and Agonists Thereof To Delay or Prevent Cardiac Remodeling |
| 05/28/2009 | US20090137465 Novel use |
| 05/28/2009 | US20090137464 Therapeutic fibrin-derived peptides and uses thereof |
| 05/28/2009 | US20090137463 Treatment for Neurodegeneration |
| 05/28/2009 | US20090137462 Pharmaceutical composition comprising cyclic somatostatin analogues |
| 05/28/2009 | US20090137461 Abuse-resistant amphetamine prodrugs |
| 05/28/2009 | US20090137460 Cross-linked glycopeptide-cephalosporin antibiotics |
| 05/28/2009 | US20090137459 Food Product for Enteral or Oral Nutrition |
| 05/28/2009 | US20090137458 Methods and compositions for increasing skin remodeling |
| 05/28/2009 | US20090137457 Pyrimidinedione derivatives |
| 05/28/2009 | US20090137456 Glucagon analogs exhibiting physiological solubility and stability |
| 05/28/2009 | US20090137455 Rapid acting and long acting insulin combination formulations |
| 05/28/2009 | US20090137454 Insulin Derivatives |
| 05/28/2009 | US20090137453 Composition comprising at least one oxazoline to inhibit migration of langerhans cells, and uses thereof |
| 05/28/2009 | US20090137452 Antagonists of the bradykinin B1 receptor |
| 05/28/2009 | US20090137451 Methods for Assessing Suitability of Cancer Patients for Treatment with Histone Deacetylase Inhibitors |